Background:
The choice whether or not to preserve the posterior cruciate ligament (PCL) in total knee arthroplasty (TKA) is coupled to the us of a PCL-retaining (CR) or a condylar (CS) insert. The CS insert is anterior-lipped (AL) to prevent anterior translation of the femur on the tibia with flexion and compensate the function of the PCL. Currently both the CR and CS insert are made of highly cr…
Background:
The choice whether or not to preserve the posterior cruciate ligament (PCL) in total knee arthroplasty (TKA) is coupled to the us of a PCL-retaining (CR) or a condylar (CS) insert. The CS insert is anterior-lipped (AL) to prevent anterior translation of the femur on the tibia with flexion and compensate the function of the PCL. Currently both the CR and CS insert are made of highly cross-linked polyethylene (HXPLE) to theoretically reduce wear related osteolysis. However, this also might diminish the fracture toughness and crack propagation of the insert. The investigators expect that due to the high contact forces on the anterior lip of the CS insert during flexion, especially in younger and more active patients, and the lower fracture toughness of HXPLE, the CS insert insert might show more migration, wear or other damage compared to the CR insert in the long-term, which might lead to more revisions in the CS insert compared to the CR insert.
To measure the migration and wear, during surgery tantalum markers will be inserted in the host bone using a marker inserter. The displacement of the prosthesis with reference to the host bone will be measured using model-based RSA. Both tantalum markers ande the inserter are already used for study purposes. However, the safety and usability are not registered before.
Objective:
The primary objective is to compare the migration of both the femoral and tibial component by the use of a CS insert or CR insert both made of HXPLE using model-based roentgen stereophotogrammetric analysis (mRSA). Furthermore, the safety and usability of the tantalum markers and the marker inserter will be determined. The secondary objective is to determine the influence of the type of insert on the wear, inducible displacement, survival and clinical outcomes.
Study design:
A randomized controlled trial
Study population:
Forty-four patients scheduled to undergo primary total knee replacement, aged below 70 years with an ASA-score of 1 or 2 will be needed in total, divided in two groups of 22 patients each.
Intervention:
One group receives an uncemented TKP with a CS insert, while the other group receives an uncemented TKP with a CR insert. Both will be placed using the MAKO-robotic arm using a kinematic balancing technique.
Outcomes:
Main study parameters are migration of the femoral and tibial components measured with model-based RSA software till 10 years postoperatively. Furthermore, the stability of the markers will be determined and the complications due to the markers and/or the marker inserter will be registered. The secondary parameters are wear, inducible displacement, survival, clinical outcomes and complications up to 10 years postoperatively.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Patients scheduled to undergo primary total knee replacement with the MAKO-robotic arm, with one of the following indications:
* Painful, disabling joint disease of the knee resulting from: non-inflammatory degenerative joint disease (including osteoarthritis, traumatic arthri…
Inclusion Criteria:
* Patients scheduled to undergo primary total knee replacement with the MAKO-robotic arm, with one of the following indications:
* Painful, disabling joint disease of the knee resulting from: non-inflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis or avascular necrosis) or rheumatoid arthritis.
* One or more compartments are involved;
* Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability (meaning a varus, valgus or flexion deformity \< 15 degrees);
* Age between 18 and 70 years;
* ASA score I or II;
* A good nutritional state of the patient;
* Patients with a completely intact PCL at the time of surgery;
* Patient is able to understand the study and is willing to participate and to sign the Informed Consent;
* Patient is able to speak and write Dutch.
Exclusion Criteria:
* Contraindications manufacturer:
* Any active or suspected latent infection in or about the knee joint;
* Distant foci of infection which may cause hematogenous spread to the implant site;
* Any mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care;
* Bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the prosthesis;
* Skeletal immaturity;
* Severe instability of the knee joint secondary to the absence of collateral ligament integrity and function;
* Metal in the operative or non-operative leg which lead to the creation of accuracy-reducing artefacts in the CT scan;
* Body Mass Index (BMI) of \> 35 kg/m2;
* Flexion contracture of 15 degrees and more;
* Varus/valgus contracture of 15 degrees and more;
* History of total or unicompartmental reconstruction of the affected joint;
* Bilateral operation;
* A Total Hip Arthroplasty (THA) on contralateral and/or ipsilateral side within the last year that is considered to have an unsatisfactory outcome (Patients with contralateral and/or ipsilateral THA \> 1 year ago with good outcome can be included in the study);
* A Total Knee Arthroplasty (TKA) on contralateral side within the last 6 months that is considered to have an unsatisfactory outcome. (Patients with contralateral TKA \> 6 months ago with good outcome can be included in the study);
* Patients who will need lower limb joint replacement for another joint within one year.
* Active or suspected latent infection in or about the knee joint;
* Osteomyelitis;
* Sepsis;
* A systemic or metabolic disorder leading to progressive bone deterioration, excluding rheumatoid arthritis;
* Vascular insufficiency, muscular atrophy;
* Neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device;
* Female patients planning a pregnancy during the course of the study;
* The patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements.
* Patients bone stock is compromised by disease or infection which cannot provide adequate support and/or fixation to the prosthesis;
* A knee fusion to the affected joint;
* Patient has a known or suspected sensitivity or allergy to one or more of the implant materials;
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
